Cervical cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TP53 2
• PD-1 19
• PD-L1 12
• PI3K 3
• AKT 1
• CTLA-4 7
• HER2 9
• CTNNB1 0
• mTOR 0
• STAT3 0
• VEGF 3
• EGFR 2
• MYC 0
• MAPK 0
• PTEN 2
• NRF2 1
• PIK3CA 3
• ERK 0
• PARP 0
• AMPK 0
• JAK 0
• TROP2 4
• YAP 0
• BRCA1 2
• GPX4 0
• HIF-1 0
• IL-6 0
• TNF 0
• FOXP3 0
• KRAS 0
• B7-H3 3
• BCL-2 0
• BRCA2 2
• HER3 1
• JNK 0
• MMP-9 0
• STING 0
• STK11 0
• AXL 0
• CD47 0
• COX-2 0
• EZH2 0
• FAK 1
• HDAC 0
• HMGB1 0
• PPAR 0
• PRAME 0
• ATM 0
• CD40 0
• CXCR4 0
• IDH 1
• LAG-3 0
• METTL3 0
• NF1 0
• NOTCH1 0
• PKM2 0
• PRMT5 0
• SHP2 0
• SIRT1 0
• ALK 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 29+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

  NCT06865677· National Cancer Institute (NCI)· Updated 21 Jan 2026

  “This protocol was terminated prematurely because the prior principal investigator departed the Institute without treating any participants.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Merck Sharp & Dohme LLC· Source

• Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

  NCT06865677· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 28
• Organoids 10
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 21
• Gene Expression Profiling 70
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 18
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 25
• Immunohistochemistry 46
• Liquid Biopsy 8
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 65
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 92
• Machine Learning 63
• Deep Learning 50
• Cohort Studies 81
• Genome-Wide Association Study 14

• FMCerNet: frequency-aware multi-label learning for fine-grained cervical cytology screening.

  Bioinformatics, Oct 2026

• Deciphering the role of microplastics-related molecular signatures in cervical cancer progression: Transcriptomic analysis and diagnostic model development.

  Biochem Biophys Res Commun, Sept 2026

• Comprehensive Analysis of Cuproptosis-Related Genes According to Cancer Stage and Their Prognostic Value in Cervical Cancer.

  Int J Mol Sci, Aug 2026

• Weighted Gene Co-Expression Network Analysis and Machine Learning Reveal that USP1 Drives Lipid Metabolism and Macrophage Polarization in Cervical Cancer Cells.

  Reprod Sci, Aug 2026

• Label-free cervical cancer detection in tissue samples using Raman spectroscopy combined with machine learning technology.

  Anal Methods, Aug 2026

• A prognostic immune signaling-related lncRNA-circRNA-mRNA network model for cervical cancer using machine learning.

  Biochem Biophys Res Commun, Jul 2026

• Preoperative PET/CT phenotype of gastric-type endocervical adenocarcinoma: integrated morphological, metabolic, serological, and explainable machine-learning analysis.

  Eur J Nucl Med Mol Imaging, Jul 2026

• [Interpretable machine learning models for preoperative precision prediction of perineural invasion in cervical cancer to support treatment decision: a multicenter retrospective study].

  Nan Fang Yi Ke Da Xue Xue Bao, Jul 2026

• A rapid detection of early-stage cervical cancer using nucleus and cytoplasm-based machine learning-driven refractive index surface plasmon resonance biosensor with ZnO-ag efficient materials.

  Spectrochim Acta A Mol Biomol Spectrosc, Jul 2026

• AI-assisted Radiomic Model for Cervical Cancer Recurrence Prediction: A Multicenter Retrospective Study with Experimental Validation.

  Radiol Imaging Cancer, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.